

Polarean Imaging PLC

09:09 07 Nov 2019

Polarean completes patient enrolment for Phase III clinical trial of MRI lung scan technology

Polarean Imaging PLC (LON:POLX) has completed patient enrolment for a Phase III clinical trial of its MRI lung scan technology.

The medical imaging specialist said it had enrolled 80 patients, 48 of which are in a lung transplant pathway while the remaining 32 are for lung resection, a process where part of the lung tissue is removed.

READ: Amphion no longer holds any shares in Polarean Imaging
 Polarean is aiming to show in the trials that its drug-device combination, which uses a type of Xenon gas in a magnetic resonance imaging (MRI) machine, is as good as current methods for diagnosing breathing problems.

The trials are now in the image and statistical analysis stage, a process that is expected to take around 10 weeks and will conclude with a readout of the trial.

The readout will then form the basis for a pre-new drug application (NDA) meeting with the US Food and Drug Administration (FDA), with a formal application to be lodged in the second quarter of next year.

Polarean added that it had appointed Alex Dusek as its vice-president of commercialisation with immediate effect, consistent with its target of achieving commercial sales following FDA approval.

"The Company is pleased to have successfully completed enrolment for its Clinical Trials and looks forward to the next stage of statistical analysis ahead of readout and the proposed submission of the NDA", said Polarean chief executive, Richard Hullahen.

"We are also pleased to welcome Alex Dusek to our team, as he brings a wealth of direct pharmaceutical industry launch preparation and commercialisation experience to Polarean, as we ramp up our commercialisation planning", he added.

In early trading on Thursday, Polarean's shares were 0.7% lower at 22.9p.

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com


No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is

Price: 32

Market Cap: £36.62 m

1 Year Share Price Graph



January 2019 September 2019 January 2020

Share Information

Code: POLX

Listing: AIM

52 week High Low
 39.5 13

Sector: Medical technology & services

Website: www.polarean.com

Company Synopsis:

Located in the Research Triangle Park area of North Carolina, Polarean Imaging PLC designs and manufactures equipment for production of hyperpolarized xenon or helium gas. When used in conjunction with MRI, these gases offer a fundamentally new and non-invasive functional imaging platform.

action@proactiveinvestors.com

provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Polarean Imaging PLC named herein, including the promotion by the Company of Polarean Imaging PLC in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).